ࡱ> NPM[ bjbj E>ΐΐ P P 84T#gggggBBB|#~#~#~#~#~#~#$&(|#BBBBB#gg#Bgg|#B|#!0#gP;8V""h##0##"!)8!)D0#!)0#8BBBBBBB##BBB#BBBB!)BBBBBBBBBP Y: SENIOR CARE CONSULTANT GROUP SAMPLE FOR LTC FACILITIES ANTICOAGULATION GUIDELINES 2007 INDICATION INR Orthopedic Total Hip and Knee Arthroplasty 1.8-2.5 Hip Fracture 1.8-2.5 Cardiology Atrial Fibrillation 2.0-3.0 Cardiomyopathy 2.0-3.0 Myocardial Infarction 2.0-3.0 Bioprosthetic Heart Valve 2.0-3.0 Mechancial Valve Replacement 2.5-3.5 Treatment of Venous Thrombosis Deep Vein Thrombosis 2.0-3.0 Pulmonary Embolism 2.0-3.0 _______________________________________ INITIAL DOSE OF WARFARIN Orthopedic for INR range of 1.8-2.5: Men: 5 mg (7.5 mg if <60 yo or >240 lbs), less if on interacting drugs Women: 5 mg (2.5 mg if >80 yo or interacting medications) All other indications for INR ranges 2.0-3.5: Men: 5 mg - 7.5 mg (2.5 mg if >80 yo) Women: 5 mg - 7.5 mg (2.5 mg if > 80 yo) Consider using larger initial doses in non-ortho patients to assure therapeutic INR within 3-4 days, especially if patient is younger, heavier and has no interacting medications Consider using smaller initial doses (i.e. 2.5 mg) in certain patients based on indication, age, sex, interacting medications/disease, nutritional status, etc. SECOND DOSE OF WARFARIN (Give same dose as day before if <0.2 increase in INR Day 1 INR 0.99 5 mg Day 2 INR 1.13 5 mg If INR increases >0.2 after the first dose, consider decreasing the dose by 25-50% (may indicate patient sensitive to warfarin) THIRD/ENSUING DOSES OF WARFARIN (If after two days of the same dose and <0.3 increase in INR, then increase dose Day 1 INR 1.00 5 mg Day 2 INR 1.13 5 mg Day 3 INR 1.21 7.5 mg (If after two days of the same dose and 0.3-0.5 increase in INR, give same dose Day 1 INR 0.97 5 mg Day 2 INR 1.03 5 mg Day 3 INR 1.35 5 mg (If >0.5, but <1.5 increase in INR after two days, decrease dose by 25-75%* Day 1 INR 0.87 5 mg Day 2 INR 1.12 5 mg Day 3 INR 1.70 2.5 mg WHEN TO HOLD WARFARIN *Consider holding if >1.5 increase in INR in 1 day even if INR does not meet criteria for hold Orthopedic for INR range 1.8-2.5 >2.5-2.9 Decrease dose by 25-75% >3.0 Hold Cardiology and Other Patients with INR 2-3 >3-3.9 Decrease dose by 25-75% >4.0 Hold Cardiology for INR range of 2.5-3.5 >3.5-4.5 Decrease dose by 25-75% >4.6 Hold DISCHARGE ORDERS Recommendations should include appropriate interval to follow-up INR, which usually should not exceed 1 week, and ideally should be 2-3 days for patients initiated in the facility. DRUG INTERACTIONS Increase INR Alcohol Amiodarone* Argatroban (see argatroban reference sheet) Azole antifungals Cimetidine Corticosteroids Macrolides (rarely azithromycin) Metronidazole* Omeprazole Phenytoin (initially) Propafenone* Rofecoxib Tamoxifen* Thyroid TMP/SMX* *Strong warfarin potentiation Possibly/Rarely Increase INR (In most cases, should not require initial dose adjustment) Acetaminophen (> 2275mg/wk) Allopurinol Celecoxib Glyburide HMG CoA Reductase Inhibitors Propoxyphene Quinidine Quinolones Ranitidine SSRIs (fluoxetine>paroxetine>sertraline) Tetracyclines Vitamin E (> 300 IU/day) Zafirlukast Zileuton Decrease INR Methimazole, PTU Barbiturates Phenytoin (> 1 week) Carbamazepine Rifampin Nutritional supplements (i.e. Boost, Ensure) Impair absorption (decrease INR) Calcium supplements Cholestyramine Fiber supplements Sucralfate Tube feeding-do not hold tube feeding Herbals that can increase INR Angelica Root Garlic Capsicum Ginko Carnitine Licorice Root Celery Papaya Extract Chamomile Papain Danshen Root Red Clover Dong Quai Sweet Clover Silvia Root Wintergreen oil Herbals that can decrease INR Avocado Green Tea Co-enzyme Q10 Psyllium Ginseng Rosehip Herbals that can increase bleeding Clove Meadowsweet Feverfew Policosanol Ginger Turmeric (Herbal list is not all-inclusive. (Most available herbal info is based on in-vitro data, animal studies, or case reports. Definitive cause-and-effect relationships have not been established. The INR should be closely monitored when any herbal is initiated or discontinued. DISEASE-STATE INR EFFECTS CHF ( Diarrhea ( Hyperthyroidism ( Infection/Fever ( Liver disease ( Malnutrition ( Pain ( Chronic alcoholism (/( Edema ( Hypothyroidism ( Tobacco use ( VITAMIN K1 PROTOCOL Standard Reversal: No active bleeding and no surgery planned within 24 hours Hold warfarin INR q am Give Vitamin K1 as follows: INR > 9 Vitamin K1 5 mg PO INR > 5 and < 9 Vitamin K1 1-2.5 mg PO INR > 3 and < 5 No Vitamin K1 INR < 3 Discontinue protocol * If patient has malabsorption disorder, biliary obstruction, or is NPO may give Vitamin K1 intravenously (consider lower dose). ** Doses of Vit K1 1 mg can be achieved by mixing 0.1 ml of the parenteral solution in some fluid and giving orally. Rapid Reversal: INR > 10 or active bleeding or surgery/procedure within 24 hours Hold warfarin INR q 6h If initial INR and subsequent INR is: INR >10 Vitamin K1 10 mg IV INR >5 but <10 Vitamin K1 5 mg IV INR > 1.5 but < 5 Vitamin K1 2 mg IV INR < 1.5 Discontinue protocol Consider use of fresh frozen plasma for rapid reversal The intramuscular route of vitamin K administration should be avoided due to the possibility of hematoma formation and dermatological reactions. (There is concern of anaphylaxis with the intravenous route. If chosen, dilute and administer slowly over 30 minutes to minimize anaphylactic reactions. (Use of high doses of vitamin K (>10mg) may cause prolonged (up to 1 week) warfarin resistance.     ";<=>?@[]abgtw   ) M N Q W   % & , : N P ӿh;h 5CJ h;CJ h 9h 5>*CJ h 6CJh 6>*CJ h CJh 59CJ h 5CJh;59B*CJphh 59B*CJph h%.5CJ h 5CJ h;5CJ h 5 h%.52 !"<=?@[\]bcdefghijklmnop$a$pqrstuvwx " A d   ) N  `@& & O P    * + 9Uop` `$a$@&gd;P g t  K U pqz<D%Fu 5 9:;ٹ񫹤} h >* h 6>* h 6 h 6CJh 56CJ h CJ h 56 h;9CJ h;5CJ h 9CJh 6>*CJh 5>*CJ h >*CJ h CJ jh CJOJQJ h 9 h 5CJh;h ._z%&Giuv !"#$@& `&dP``$5 K]hxv@&$a$;uvabnoxyNOm  ,-8<vnh 59>*h 5>*CJ h 5CJ j4h 5CJ h 56 h CJH*h h CJmHsH h 5 h CJ h 5CJh 5>*CJ h 6CJh 56>*CJh 56>* h 6h 56CJ h CJ h >* h >*CJ(%3LXab+=Rxy>@&`>@&.JOm ,8>I[m} Z^Z`$a$@&<=GHYZkl{|4Z[hlmp}~˺˵ykyh h CJH*mHsHh h CJmHsHh h 5>*CJmHsHh h 5CJmHsH h CJH* h CJh h >*!h h 59CJH*mHsHh h 59CJmHsHh h CJmHsH jh CJ h CJ jh CJ'4BLhM[ & F]$]a$^$a$gdf/ & F@&^_  (+Mξήήܠܚ||ssl|| h CJH*h 56CJh 5>*CJ h >*h 5CJH* h 5CJ h CJh h CJH*mHsHh h 5>*CJmHsHh h 5CJH*mHsHh h 5CJmHsHh h CJmHsHh hf/CJmHsHh CJmHsH*[dTUgd `Z^Z`$ `Z^Z`a$$ & F h`ZZ^Z`a$ ` & F h & FTU0\򲮲hbjhbU h >*CJ jh CJOJQJh CJOJQJh CJ OJQJh 5>*CJ h 5CJ h CJ h CJH* `Z^Z`gd C 00P0BP= /!"#$8% P 8Dp^ 2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH D`D Normal1$CJ_HhmH sH tH B@B  Heading 1$@& 56>*CJD@D  Heading 2$@& `5CJB@B  Heading 3 $1$@& 5huFF  Heading 4$@& ` 5>*CJF@F  Heading 5$1$@&^hu>@>  Heading 6$@& 6>*CJ<@<  Heading 7$@&>*CJ\\  Heading 8&$$ `Z@&^Z`a$ 5>*CJDA D Default Paragraph FontViV  Table Normal :V 44 la (k (No List <& < Footnote Reference@Y@@  Document Map-D OJQJ6B@6 Body Text5CJ:P@": Body Text 25CJ@Q@2@ Body Text 31$ 5hu4B4 Header  !4 R4 Footer  !PK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK]  > P ;<p $[8@0(  B S  ?ANdn"$KM{] g      L W X ` o z  * G Q hlnpt|-4f j h333"<<>>@]ccs4LMd1;<<>>cc" i M>gHa 2Ht U"F)sF# O]#  )*$ V(&f85 M] G4Jw tj~  hh^h`OJQJo( hh^h`OJQJo(hh^h`o(.hh^h`o(. hh^h`OJQJo( hh^h`OJQJo( hh^h`OJQJo( hh^h`OJQJo( hh^h`OJQJo(88^8`o(. hh^h`OJQJo( hh^h`OJQJo(hh^h`o(. hh^h`OJQJo(U"V(&MG4JwHa"85sF#tj~O]# )*$M]i2Ht!#f/bvPqTV %.;@@`@UnknownG* Times New Roman5Symbol3. * ArialG OWP MathASymbolSMonotype SortsSymbol;Wingdings5. *aTahomaA BCambria Math" hs&s&VjfD 'D '! d2Q HX? 2!xxFAIRVIEW SOUTHDALE HOSPITALJSTROSH1MaxineD         Oh+'0 , L X d p|FAIRVIEW SOUTHDALE HOSPITAL JSTROSH1 Normal.dotmMaxine2Microsoft Office Word@F#@u@C ;8@C ;8D՜.+,0 hp  FAIRVIEW MEDICAL STAFF'  FAIRVIEW SOUTHDALE HOSPITAL Title !"#$%&')*+,-./0123456789:;<>?@ABCDFGHIJKLORoot Entry F d;8QData  1Table(e)WordDocumentE>SummaryInformation(=DocumentSummaryInformation8ECompObjy  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q